KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Accounts Payables (2017 - 2025)

Novartis Ag (NVS) has disclosed Accounts Payables for 9 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 2.54% to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, down 2.54% year-over-year, with the annual reading at $4.5 billion for FY2025, 2.54% down from the prior year.
  • Accounts Payables hit $4.5 billion in Q4 2025 for Novartis Ag, down from $4.6 billion in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.6 billion in Q4 2021 to a low of $4.5 billion in Q4 2025.
  • Historically, Accounts Payables has averaged $4.9 billion across 5 years, with a median of $4.9 billion in 2023.
  • Biggest five-year swings in Accounts Payables: increased 2.78% in 2021 and later dropped 7.33% in 2022.
  • Year by year, Accounts Payables stood at $5.6 billion in 2021, then fell by 7.33% to $5.1 billion in 2022, then dropped by 4.28% to $4.9 billion in 2023, then decreased by 7.19% to $4.6 billion in 2024, then fell by 2.54% to $4.5 billion in 2025.
  • Business Quant data shows Accounts Payables for NVS at $4.5 billion in Q4 2025, $4.6 billion in Q4 2024, and $4.9 billion in Q4 2023.